Medical interpretation AI
No Barrier
No Barrier is a vendor-hosted AI language-access platform used by healthcare organizations during clinical encounters. Its current materials describe real-time interpretation across 295+ language access options, visual supports, bilingual discharge notes, and a built-in route to human interpreters. Faster language access may strengthen patient understanding and participation, but this remains institution-led: the care organization controls the system, and public evidence does not establish what patients are told, how refusal works in practice, or how they can review and correct a disputed interpretation. Current terms require another method and human verification. An external landscape report documents No Barrier's market presence and stated quality controls, but independent product validation across languages and care settings was not found.
Public-source research has been drafted, often with AI assistance. No comprehensive human review is recorded unless the profile provenance says so.
Summary judgment · 43% toward patient-directed
Mixed, institution-led language-access aid
No Barrier can reduce a serious language-access barrier by enabling faster, direct communication. The healthcare organization selects, pays for, configures, and governs the platform, while a patient's notice, refusal, access to a human interpreter, and ability to resolve a mistake remain deployment-dependent.
Patient agency
How this tool changes agency
Real-time interpretation, visual supports, and bilingual discharge notes could support questions, consent, instructions, and next steps. HHS guidance requires qualified human review of machine-translated critical, complex, or accuracy-essential text at covered entities, which is relevant to discharge-note workflows. The benefit depends on accurate interpretation, patient notice, an appropriate human alternative, and a way to resolve misunderstandings.
Terms say customers must offer patients the platform or another method. A July 2026 vendor article says the platform can route to a human interpreter when a patient or provider prefers one, and HHS guidance says covered entities must offer a qualified interpreter when interpretation is requested. Public evidence does not establish whether patients are told this, how they trigger it, how long it takes, or whether refusal changes care timing or experience.
Patient-facing signals
Who does this AI serve?
The SaaS product, pilot, pricing, and workflow materials target healthcare organizations and care teams. Patients with limited English proficiency are direct participants and may benefit from communication access, but they are not the documented purchasers, administrators, or governors.
Can patients tell AI is involved?
Buyer-facing materials clearly describe AI interpretation, and the homepage advertises configurable disclosure. The terms and privacy policy make customers responsible for needed permissions, consents, and notices. No patient-facing script, sign, in-app notice, or evidence that disclosure occurs before use and is understood was found.
Can patients meaningfully choose?
Terms say customers must offer patients the platform or another method. A July 2026 vendor article says the platform can route to a human interpreter when a patient or provider prefers one, and HHS guidance says covered entities must offer a qualified interpreter when interpretation is requested. Public evidence does not establish whether patients are told this, how they trigger it, how long it takes, or whether refusal changes care timing or experience.
Can patients correct or challenge what the AI produces?
Terms make the authorized user responsible for evaluating and verifying results, and a patient can seek clarification in the live conversation. No public workflow gives patients a transcript, translation review, correction, complaint, or adverse-event route after the encounter.
Does it help patients understand or act?
Real-time interpretation, visual supports, and bilingual discharge notes could support questions, consent, instructions, and next steps. HHS guidance requires qualified human review of machine-translated critical, complex, or accuracy-essential text at covered entities, which is relevant to discharge-note workflows. The benefit depends on accurate interpretation, patient notice, an appropriate human alternative, and a way to resolve misunderstandings.
Text findings
Who is left out or burdened?
Coverage is broad, but fit and performance remain insufficiently disclosed
No Barrier distinguishes 295+ language-access options from AI coverage for selected languages and human-interpreter coverage for others. Public materials cite some Spanish dialects and recognize that human interpreters can be preferable for emotional encounters. A 2026 CHCF landscape report recommends language- and content-specific validation plus community participation. No product-specific performance results were found for languages, dialects, accents, hearing or speech disabilities, low literacy, cognitive impairment, pediatric care, noisy settings, or culturally complex discussions.
What happens to patient data?
Seven-day default claimed, but longer retention and enduring de-identified use are possible
The security page says encounter content is deleted after seven days with no exceptions, backups, or archives. Newer product material says seven days unless a longer period is agreed in writing, and another product page calls retention admin-configurable. Terms allow perpetual use of anonymized, de-identified, or pseudonymized information to improve products, while the privacy policy allows de-identified use and third-party disclosure. Public materials do not reconcile these statements or establish patient access, export, deletion, current recipients, BAA terms, or deployment-specific retention.
Are the clinical boundaries clear?
Partial
Terms say the platform is not medical advice or a standalone basis for clinical decisions, may produce incorrect results, requires human verification, and should be offered alongside another method. The vendor says human interpreters are preferable for emotional situations such as end-of-life care. HHS guidance requires qualified human review of critical machine-translated text at covered entities, and CHCF recommends risk-tiered human involvement. Public evidence does not establish deployment rules for consent, diagnosis disclosure, emergencies, pediatrics, adverse events, bilingual discharge-note review, or mandatory human escalation.
Who defined what good looks like?
Mostly vendor- and organization-defined
The current public evidence emphasizes connection time, throughput, cost, coverage, and vendor-reported accuracy. A vendor article reports a 91-sentence English-Spanish comparison scored by external interpreters, but the full protocol and independent publication were not found. CHCF independently maps No Barrier's market presence and stated quality controls based on interviews and company materials, not a product validation. A 2026 patient-preference study supports a context-sensitive AI and human model, but it does not evaluate No Barrier.
Review provenance
Criteria
Same HugoScore CAIHL-derived criteria for every tool. Public criteria are in site/data/criteria.json and the fuller method is in SCORING_FRAMEWORK.md.
Reviewer
AI-assisted public-source draft refreshed in OpenAI Codex. No named human reviewer is recorded.
AI / model
OpenAI Codex / GPT-5.
Human review
No comprehensive human review has been completed or claimed for this draft profile.
Review date
2026-07-20
Limitations
No hands-on product use, patient-facing notice or consent observation, interview, customer contract or BAA review, audit report, incident record, source-data or deletion test, accessibility evaluation, or independent product-specific validation. Vendor claims and the vendor-published comparison are not treated as independent evidence. HHS and CHCF sources provide governance context, not a finding that a particular deployment is compliant or noncompliant.
Review method
Public-source refresh of official product, FAQ, AI-interpreting, human-escalation, security, privacy, terms, and HIPAA materials, the vendor's comparative study, the 2026 California Health Care Foundation landscape report, current HHS Section 1557 language-access guidance, and the PubMed abstract for a 2026 peer-reviewed patient-preference study. No product access, patient or customer interview, customer contract or BAA review, incident-data review, security-audit inspection, or independent No Barrier accuracy, safety, equity, or outcome validation.
Draft profile · Medium draft, with current official documentation plus external landscape and patient-preference evidence. No independent No Barrier product validation